---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-011080"
form_type: "8-K"
ticker: "CORT"
cik: "0001088856"
company_name: "CORCEPT THERAPEUTICS INC"
filed_at: "2026-02-24T23:59:59+00:00"
generated_at: "2026-05-16T00:38:34.436051+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Corcept Q4 revenue $202.1M, FY2025 $761.4M; guides FY2026 revenue $900M-$1B

## Summary
- Q4 2025 revenue $202.1M (vs $181.9M Q4 2024); full-year revenue $761.4M (vs $675.0M in 2024).
- Diluted EPS: Q4 $0.20, FY2025 $0.82 (vs Q4 2024 $0.26, FY2024 $1.23). Net income declined due to stock repurchases and operational costs.
- Cash and investments $532.4M at Dec 31, 2025; spent $245.9M on stock repurchases in 2025.
- FY2026 revenue guidance $900M-$1B; expects continued Cushing's syndrome business growth.
- PDUFA date July 11, 2026 for relacorilant NDA in platinum-resistant ovarian cancer; FDA engaged after CRL for Cushing's NDA.

## SEC filing metadata
- accession: 0001628280-26-011080
- form_type: 8-K
- ticker: CORT
- cik: 0001088856
- company_name: CORCEPT THERAPEUTICS INC
- filed_at: 2026-02-24T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1088856/000162828026011080/0001628280-26-011080-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1088856/000162828026011080/cort-20260224.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-011080
- JSON: https://secwatch.observer/filing/0001628280-26-011080.json
- Plain text: https://secwatch.observer/filing/0001628280-26-011080.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.